MedTrace Logo

Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke

NCT05745311 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 240

Last updated 2023-02-28

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

The KPCXM18 injection

Intravenous infusion

DRUG

Placebo

Intravenous infusion

Sponsors & Collaborators

  • Kunming Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Yongjun Wang, MD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2024-05-01
Completion
2024-07-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05745311 on ClinicalTrials.gov